Analysis of COVID-19 pandemics in Kazakhstan.
Adolescent
Adult
Age Factors
Aged
COVID-19
/ complications
Carrier State
/ epidemiology
Child
Comorbidity
Cough
/ epidemiology
Cross-Sectional Studies
Female
Humans
Kazakhstan
/ epidemiology
Male
Middle Aged
Pandemics
Pharyngitis
/ epidemiology
Pneumonia
/ epidemiology
Respiratory Distress Syndrome
/ epidemiology
Retrospective Studies
SARS-CoV-2
Sex Factors
Young Adult
COVID-19
Comorbidity
Coronavirus
Epidemiology
Mortality
Journal
Journal of research in health sciences
ISSN: 2228-7809
Titre abrégé: J Res Health Sci
Pays: Iran
ID NLM: 101480094
Informations de publication
Date de publication:
26 May 2021
26 May 2021
Historique:
received:
07
04
2021
accepted:
09
05
2021
revised:
05
05
2021
entrez:
1
9
2021
pubmed:
2
9
2021
medline:
16
9
2021
Statut:
epublish
Résumé
This study aimed to analyze the demographic and epidemiological features of identified COVID-19 cases in Kazakhstan. A cross-sectional study. This cross-sectional study aimed to analyze COVID-19 cases (n=5116) collected from March 13 to June 6, 2020, in Kazakhstan. The data were obtained from a state official medical electronic database. The study investigated the geographic and demographic data of patients as well as the association of COVID-19 cases with gender and age. The prevalence of symptoms, the presence of comorbidities, complications, and COVID-19 mortality were determined for all patients. The mean±SD age of the patients in this study was 34.8±17.6 years, and the majority (55.7%) of COVID-19 cases were male and residents of cities (79.6%). In total, 80% of the cases had the asymptomatic/mild form of the disease. Cough (20.8 %) and sore throat (17.1%) were the most common symptoms among patients, and pneumonia was diagnosed in 1 out of 5 cases. Acute respiratory distress syndrome (ARDS) was recorded in 1.2% of the patients. The fatality rate was 1% in the study population and lethality was 2.6 times higher in males compared to females. Each additional year in age increased the probability of COVID-19 infection by 1.06 times. The presence of cardiovascular, diabetes, respiratory, and kidney diseases affected the rate of mortality (P<0.05). The results demonstrated a high proportion (40%) of the asymptomatic type of coronavirus infection in the Kazakhstan population. The severity of COVID-19 symptoms and lethality were directly related to the age of patients and the presence of comorbidities.
Sections du résumé
BACKGROUND
BACKGROUND
This study aimed to analyze the demographic and epidemiological features of identified COVID-19 cases in Kazakhstan.
STUDY DESIGN
METHODS
A cross-sectional study.
METHODS
METHODS
This cross-sectional study aimed to analyze COVID-19 cases (n=5116) collected from March 13 to June 6, 2020, in Kazakhstan. The data were obtained from a state official medical electronic database. The study investigated the geographic and demographic data of patients as well as the association of COVID-19 cases with gender and age. The prevalence of symptoms, the presence of comorbidities, complications, and COVID-19 mortality were determined for all patients.
RESULTS
RESULTS
The mean±SD age of the patients in this study was 34.8±17.6 years, and the majority (55.7%) of COVID-19 cases were male and residents of cities (79.6%). In total, 80% of the cases had the asymptomatic/mild form of the disease. Cough (20.8 %) and sore throat (17.1%) were the most common symptoms among patients, and pneumonia was diagnosed in 1 out of 5 cases. Acute respiratory distress syndrome (ARDS) was recorded in 1.2% of the patients. The fatality rate was 1% in the study population and lethality was 2.6 times higher in males compared to females. Each additional year in age increased the probability of COVID-19 infection by 1.06 times. The presence of cardiovascular, diabetes, respiratory, and kidney diseases affected the rate of mortality (P<0.05).
CONCLUSION
CONCLUSIONS
The results demonstrated a high proportion (40%) of the asymptomatic type of coronavirus infection in the Kazakhstan population. The severity of COVID-19 symptoms and lethality were directly related to the age of patients and the presence of comorbidities.
Identifiants
pubmed: 34465636
pii: 6730
doi: 10.34172/jrhs.2021.52
pmc: PMC8957677
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e00512Références
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Clin Microbiol Infect. 2020 Jun;26(6):767-772
pubmed: 32304745
Rev Med Virol. 2021 Mar;31(2):e2171
pubmed: 33350025
Rheumatol Int. 2020 Aug;40(8):1351-1352
pubmed: 32514608
Ann Intern Med. 2020 Sep 1;173(5):362-367
pubmed: 32491919
Gut. 2020 Jun;69(6):1002-1009
pubmed: 32213556
Travel Med Infect Dis. 2020 Mar - Apr;34:101623
pubmed: 32179124
North Clin Istanb. 2020 Apr 14;7(3):210-213
pubmed: 32478290
Int J Surg. 2020 Sep;81:1-8
pubmed: 32730205
J Appl Physiol (1985). 2020 Jun 1;128(6):1533-1538
pubmed: 32437244
J Hepatol. 2021 Jan;74(1):168-184
pubmed: 33038433
J Microbiol Immunol Infect. 2020 Jun;53(3):404-412
pubmed: 32173241
Eur Respir J. 2020 May 7;55(5):
pubmed: 32269088
PeerJ. 2020 Nov 9;8:e10345
pubmed: 33240654
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Trends Mol Med. 2020 May;26(5):483-495
pubmed: 32359479
J Allergy Clin Immunol. 2020 Jul;146(1):110-118
pubmed: 32294485
Clin Kidney J. 2020 Jul 16;13(3):297-306
pubmed: 32699615
J Immunol. 2017 May 15;198(10):4046-4053
pubmed: 28373583
JAMA. 2020 Apr 28;323(16):1612-1614
pubmed: 32191259
Int J Antimicrob Agents. 2020 Mar;55(3):105924
pubmed: 32081636
PLoS One. 2020 Jun 23;15(6):e0234765
pubmed: 32574165
J Infect. 2020 Jun;80(6):656-665
pubmed: 32283155
Aging (Albany NY). 2020 Jul 13;12(13):12493-12503
pubmed: 32658868
Gene Rep. 2020 Dec;21:100891
pubmed: 33015411
J Res Health Sci. 2021 Apr 24;21(2):e00515
pubmed: 34465638
Hum Genomics. 2020 Dec 22;14(1):47
pubmed: 33353565
Front Med (Lausanne). 2020 Nov 12;7:570614
pubmed: 33282887
Int J Environ Res Public Health. 2020 Nov 04;17(21):
pubmed: 33158234
Infect Control Hosp Epidemiol. 2020 Oct;41(10):1196-1206
pubmed: 32408911
Health Policy Technol. 2020 Dec;9(4):639-648
pubmed: 32874851
J Korean Med Sci. 2020 Jun 22;35(24):e227
pubmed: 32567261
Ann Clin Microbiol Antimicrob. 2020 Dec 7;19(1):58
pubmed: 33287846
JAMA Netw Open. 2020 Dec 1;3(12):e2031756
pubmed: 33315116
Allergy. 2021 Feb;76(2):428-455
pubmed: 33185910
Paediatr Int Child Health. 2021 Feb;41(1):76-82
pubmed: 33315538
Int J Med Sci. 2021 Jan 1;18(1):120-127
pubmed: 33390780
Sci Rep. 2020 Nov 26;10(1):20731
pubmed: 33244144
Biomed Microdevices. 2020 Nov 24;22(4):83
pubmed: 33230627
BMC Biol. 2020 Nov 30;18(1):186
pubmed: 33256718
Int J Infect Dis. 2020 May;94:91-95
pubmed: 32173574
Ann Intern Med. 2020 May 05;172(9):577-582
pubmed: 32150748
Transbound Emerg Dis. 2021 Nov;68(6):3288-3304
pubmed: 33207070
Front Med. 2020 Apr;14(2):126-135
pubmed: 32240462
J Res Health Sci. 2021 Jan 18;21(1):e00508
pubmed: 34024766
Math Comput Simul. 2021 Mar;181:138-149
pubmed: 33041473
Diagnosis (Berl). 2020 Nov 18;7(4):347-348
pubmed: 32651980
Int J Biol Sci. 2021 Jan 1;17(1):97-106
pubmed: 33390836
BMC Public Health. 2020 Nov 27;20(1):1809
pubmed: 33246432